Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJ9ZIY)

Drug Name
CK-2017357 Drug Info
Synonyms
Tirasemtiv; 1005491-05-3; Tirasemtiv(CK-2017357); CK-2017357; UNII-G8WSM7R635; G8WSM7R635; 5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one; CK 2017357; 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2-ol; 2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-;2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-; Tirasemtiv [USAN:INN]; Tirasemtiv (USAN/INN); SCHEMBL976988; GTPL8280; tiraseMtiv (CK-2017357); CHEMBL3039529; EX-A367; DTXSID90143379; RSQGZEAXODVTOL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
23729157
ChEBI ID
CHEMBL3039529
CAS Number
CAS 1005491-05-3
TTD Drug ID
D07EBF

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.47 0.00e+0 34/36 (94.44%) PRIM1;MCM7;MCM5;...
Spliceosome 2.03 3.40e-3 101/150 (67.33%) PUF60;HNRNPM;SRSF6;...
Ribosome biogenesis in eukaryotes 2.01 2.26e-3 52/108 (48.15%) NVL;IMP4;GNL3L;...
Mismatch repair 1.90 1.36e-2 22/23 (95.65%) PCNA;EXO1;POLD2;...
Base excision repair 1.88 1.09e-2 29/33 (87.88%) POLE2;PCNA;HMGB1;...
RNA degradation 1.85 1.02e-2 53/79 (67.09%) TENT4A;MTREX;EXOSC10;...
Mineral absorption 1.71 3.69e-2 48/60 (80%) MT1X;MT1E;MT1F;...
RNA transport 1.70 3.65e-2 128/186 (68.82%) EEF1A2;THOC6;TARDBP;...
Cell cycle 1.68 4.30e-2 110/124 (88.71%) PLK1;CCNB1;CHEK1;...
Fanconi anemia pathway 1.67 4.14e-2 36/54 (66.67%) FANCG;BRCA1;RPA3;...
Homologous recombination 1.65 4.82e-2 35/41 (85.37%) BRCA1;POLD2;RPA3;...
IL-17 signaling pathway -1.77 3.38e-2 84/94 (89.36%) MAPK14;JUND;TRAF4;...
NOD-like receptor signaling pathway -1.79 2.79e-2 145/181 (80.11%) PLCB1;MAPK9;PSTPIP1;...
Rheumatoid arthritis -1.79 3.48e-2 78/93 (83.87%) CTSL;CTLA4;ATP6V0C;...
Mitophagy -1.82 2.95e-2 56/68 (82.35%) CALCOCO2;CSNK2A2;BCL2L13;...
Th1 and Th2 cell differentiation -1.84 3.80e-2 80/92 (86.96%) JAK2;RELA;IL13;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H